PRRT2 and telomere syndrome: Fortunately, a recent phase I study of bryostatin‐1 (20 μg/m2 q4 wk) and temsirolimus (an approved inhibitor mTOR for the treatment of metastatic renal cell carcinoma) showed optimistic results of PKC inhibition as well as mTOR signaling blockade by acting on both p70‐S6 serine/threonine kinase (mTOR complex 1) and mTOR complex 2 in patients with advanced STS and metastatic renal cell carcinoma 143.